Cargando…
Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis
The good pathological response of primary tumors (PTs) to neoadjuvant immunotherapy has been acknowledged in non-small cell lung cancer (NSCLC), however, it remains unclear whether neoadjuvant immunotherapy shows consistent effects in metastatic lymph nodes (LNs). We compared the pathological respon...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478833/ https://www.ncbi.nlm.nih.gov/pubmed/36109085 http://dx.doi.org/10.1136/jitc-2022-005160 |
_version_ | 1784790661735645184 |
---|---|
author | Zhai, Wen-Yu Zhao, Ze-Rui Chen, Si Yu, Hui Lin, Yao-Bin Wang, Yi-Zhi Long, Hao |
author_facet | Zhai, Wen-Yu Zhao, Ze-Rui Chen, Si Yu, Hui Lin, Yao-Bin Wang, Yi-Zhi Long, Hao |
author_sort | Zhai, Wen-Yu |
collection | PubMed |
description | The good pathological response of primary tumors (PTs) to neoadjuvant immunotherapy has been acknowledged in non-small cell lung cancer (NSCLC), however, it remains unclear whether neoadjuvant immunotherapy shows consistent effects in metastatic lymph nodes (LNs). We compared the pathological response of PT and nodal downstaging using a pooled analysis to assess the effect of neoadjuvant immunotherapy on LNs. Original articles reporting the tumor major pathological response (ypT(MPR)), pathological complete response (ypT0) and nodal downstaging following neoadjuvant immunotherapy in NSCLC were retrieved. The OR and 95% CI were calculated by Review Manager V.5.3. Subgroup analysis was performed according to the neoadjuvant therapy regimen used. A total of 209 patients from 6 studies were included in this analysis. The frequency of nodal downstaging was comparable to that of ypT(MPR) (OR 1.31; 95% CI 0.84 to 2.05; p=0.24). Interestingly, ypN0 was observed more frequently than ypT0 (OR 3.26; 95% CI 2.06 to 5.16; p<0.0001). However, this difference was not observed in the subgroup of cN2 patients who underwent immune checkpoint inhibitor monotherapy (OR 1.58; 95% CI 0.56 to 4.48; p=0.39). Neoadjuvant immunotherapy results in satisfactory response in metastatic LN. Patients had a high probability of node clearance when ypT0 was confirmed, especially in patients treated with immunochemotherapy. |
format | Online Article Text |
id | pubmed-9478833 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-94788332022-09-17 Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis Zhai, Wen-Yu Zhao, Ze-Rui Chen, Si Yu, Hui Lin, Yao-Bin Wang, Yi-Zhi Long, Hao J Immunother Cancer Commentary The good pathological response of primary tumors (PTs) to neoadjuvant immunotherapy has been acknowledged in non-small cell lung cancer (NSCLC), however, it remains unclear whether neoadjuvant immunotherapy shows consistent effects in metastatic lymph nodes (LNs). We compared the pathological response of PT and nodal downstaging using a pooled analysis to assess the effect of neoadjuvant immunotherapy on LNs. Original articles reporting the tumor major pathological response (ypT(MPR)), pathological complete response (ypT0) and nodal downstaging following neoadjuvant immunotherapy in NSCLC were retrieved. The OR and 95% CI were calculated by Review Manager V.5.3. Subgroup analysis was performed according to the neoadjuvant therapy regimen used. A total of 209 patients from 6 studies were included in this analysis. The frequency of nodal downstaging was comparable to that of ypT(MPR) (OR 1.31; 95% CI 0.84 to 2.05; p=0.24). Interestingly, ypN0 was observed more frequently than ypT0 (OR 3.26; 95% CI 2.06 to 5.16; p<0.0001). However, this difference was not observed in the subgroup of cN2 patients who underwent immune checkpoint inhibitor monotherapy (OR 1.58; 95% CI 0.56 to 4.48; p=0.39). Neoadjuvant immunotherapy results in satisfactory response in metastatic LN. Patients had a high probability of node clearance when ypT0 was confirmed, especially in patients treated with immunochemotherapy. BMJ Publishing Group 2022-09-15 /pmc/articles/PMC9478833/ /pubmed/36109085 http://dx.doi.org/10.1136/jitc-2022-005160 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Commentary Zhai, Wen-Yu Zhao, Ze-Rui Chen, Si Yu, Hui Lin, Yao-Bin Wang, Yi-Zhi Long, Hao Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis |
title | Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis |
title_full | Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis |
title_fullStr | Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis |
title_full_unstemmed | Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis |
title_short | Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis |
title_sort | response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478833/ https://www.ncbi.nlm.nih.gov/pubmed/36109085 http://dx.doi.org/10.1136/jitc-2022-005160 |
work_keys_str_mv | AT zhaiwenyu responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis AT zhaozerui responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis AT chensi responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis AT yuhui responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis AT linyaobin responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis AT wangyizhi responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis AT longhao responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis |